Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Long-Term Deferred Tax (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Long-Term Deferred Tax for 4 consecutive years, with $25.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Long-Term Deferred Tax fell 7.51% to $25.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $25.0 million, a 7.51% decrease, with the full-year FY2024 number at $26.6 million, down 10.32% from a year prior.
  • Long-Term Deferred Tax was $25.0 million for Q3 2025 at Centessa Pharmaceuticals, down from $25.4 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $29.6 million in Q4 2023 to a low of $3.5 million in Q4 2022.
  • A 4-year average of $25.2 million and a median of $26.8 million in 2023 define the central range for Long-Term Deferred Tax.
  • Peak YoY movement for Long-Term Deferred Tax: skyrocketed 744.16% in 2023, then decreased 11.27% in 2025.
  • Centessa Pharmaceuticals' Long-Term Deferred Tax stood at $3.5 million in 2022, then surged by 744.16% to $29.6 million in 2023, then decreased by 10.32% to $26.6 million in 2024, then fell by 5.88% to $25.0 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Long-Term Deferred Tax are $25.0 million (Q3 2025), $25.4 million (Q2 2025), and $26.4 million (Q1 2025).